Clarus Pitch Deck | Pivot Branding

Clarus

The Challenge

Clarus needed to prepare for investor pitches with a clear and compelling story.
The science was groundbreaking, but…

The narrative was highly technical and difficult for non-scientists to grasp
Early pitch materials were dense and lacked emotional connection
No clear throughline tied the story, science, and market opportunity together

Without clarity, the risk was that investors wouldn’t see the full potential of the platform.

The Solution

A focused sprint to transform complex science into a story investors could understand and get behind:

Messaging → Simple narrative built around “speaking the immune system’s language”
Pitch Script → Structured delivery with story-driven opening and analogies
Pitch Deck → Simplified visuals, proof slides, and clear investor takeaways
Speaker Coaching → Coached founder on delivery, pacing, and storytelling

The Result

In just a few weeks:

A cohesive investor story that bridges science and business
A beautiful deck that shows both proof of science and market traction
Messaging that sparks curiosity
The founder pitched at a major investor event and became one of the top two favorite speakers
Sparked active interest from two investors, opening doors for future funding

It’s 1890. ➡️ An Italian immigrant named Mr. Zola walks into a New York doctor’s office with a massive tumor on his neck.

The diagnosis is grim. At the time, cancer was a death sentence.

Years later, Mr. Zola walks back into that same office... but the tumor is gone.

Not because of a miracle cure from the doctor. While in Italy, Zola had contracted a severe infection. That infection had triggered his immune system to recognize the tumor and destroy it. That’s right, his body fought off the cancer not with medicine, but because the infection made his immune system identify the tumor as something dangerous.
That story lit a fire for me.

It showed that if you can speak the right language to the immune system, you can train it to fight what it previously ignored.

The challenge, and the opportunity, is finding a way to do that safely, predictably, and at scale.

That’s exactly what Clarus has achieved.

There are a couple ways that antigens can be delivered into the body. Think about it like this.

Imagine a boss needs an important letter hand delivered to him in New York. ➡️ One hundred delivery men with the letter are put on a plane and dropped into the city. They wander the streets, hoping to bump into the boss.

That is how most therapies deliver antigens. They release them into the bloodstream and hope they get noticed by the dendritic cells (the boss in this example).

With Clarus, ➡️ a single delivery man is guided straight to the boss. He is able to communicate clearly with him and delivers the letter.

Communication with your immune system is everything. Clarus makes sure the message is received loud and clear, in its own language, so the body responds with full strength.

Our secret sauce is that the antigen is delivered directly ➡️ to dendritic cells by our VLPs.

That means the immune response is stronger and more➡️ effective. Think back to our delivery analogy. Instead of wandering the streets, the letter goes straight to the boss, the dendritic cells. In trials, that precision has doubled efficacy.

It also means ➡️ fewer side effects, because we need 10x less of the antigen. We’re sending just one delivery man, and he’s going exactly where he needs to go.

And➡️ the result lasts longer. By presenting the antigen at the exact moment innate immunity is triggered, the body treats it like a real threat and locks it into memory for life.

But don't just take my word for it. We have data from a study to show how effective Clarus really is.

On the left, you see the control group with no active therapy. As expected, very high levels of infectious agent after infection.

In the middle, you see a standard therapy dose. It helps, but there’s still a lot of infectious disease present.

In the third green bar, you see what happens when we pair just one-tenth of that therapy dose with Clarus' VLP.

Infectious levels drop by a hundred-fold, far below both the control and the standard treatment.

Our technology is not something just anyone can copy. This is patented technology exclusive to Clarus, backed by decades of know-how by our team, which gives Clarus a strong moat.

This moment happens to be the perfect time to invest in solving this problem.

➡️First of all, public trust in vaccines and therapies is fragile. People need safer, more effective treatments they can believe in.

➡️Secondly, two billion dollars has been wasted just this year on inefficient antigen delivery and overproduction.

➡️Thirdly, Clarus’s patented VLP tech is now ready to scale. It enables up to 10x antigen stretching, making large-scale distribution feasible.

The stakes are high for anyone who’s ever known someone with cancer. Most patients are given only a handful of treatment options. And for too many, those options simply don’t work. That’s why getting new therapies to patients faster is so critical. If we don’t solve this, people will continue facing limited choices... and lives will continue being lost because the right treatment never reached them.

We’re not starting from scratch.
We have secured ➡️ $14.3 million in non-dilutive funding which has gotten us through our research phase.

We've also already secured ➡️ $1.3 million in convertible note debt to begin our Go To Market Phase.

➡️ Now, we are raising $5 million in convertible notes or equity to bridge to manufacturing readiness.

This funding will allow us to
begin targeting the 187 cell therapy companies capable of using our platform system. 20 of those are already primed to be perfect fits.

We estimate our first licensing revenue will begin in ➡️ 12 to 18 months.

Our entry into human immunotherapy trials will also begin around this time.

This is early equity in a biotech platform with the rare combination of patents, proven data, and a straightforward path to commercialization.

There are two phases in our go to market plan.

➡️First, we’re in active discussions with two major cattle and poultry vaccine companies.

These markets are price-sensitive, which makes our cost advantage a huge win.

➡️Next, we plan to move into Human Immunotherapy.

➡️Our one-and-done treatments have massive potential.

We can address 10 percent of the $282 billion dollar cancer market.

The higher efficacy and cost savings in manufacturing presents an enormous opportunity in these markets for both material sales and licensing.

Our leadership team brings deep experience and a proven track record in biopharma.

Together, we have 124 years of combined industry experience.

Between us, we’ve built five startups, taken three companies to successful exits, and even contributed to work recognized with a Nobel Peace Prize.

Our team knows how to navigate the challenges of biotech and has the relationships to move breakthrough science all the way to market.

Remember Mr. Zola? He survived because an infection accidentally spoke the language of cancer to his immune system.

Clarus has found a way to do that intentionally. Safely. Predictably.

For pharma, it means breakthrough science that actually works in the real world.
For investors, it means scalable licensing revenue in massive global markets.

For patients it means safer treatments, fewer side effects, and more hope.

Together, we can make a lasting impact on medicine.

The Design BEFORE

Work

Have You Seen This Yet?

pitch deck design storybrand CPG beer company